Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2

Conditions

Breast Neoplasms 3135Neoplasms 2480Carcinoma, Non-Small-Cell Lung 1877Prostatic Neoplasms 1635Colorectal Neoplasms 1422Lung Neoplasms 1308Multiple Myeloma 935Neoplasm Metastasis 927Leukemia, Myeloid, Acute 883Pancreatic Neoplasms 861Ovarian Neoplasms 811Melanoma 792Carcinoma, Hepatocellular 739Stomach Neoplasms 649Brain Neoplasms 638Squamous Cell Carcinoma of Head and Neck 637Recurrence 637Head and Neck Neoplasms 606Glioblastoma 569Lymphoma 550Uterine Cervical Neoplasms 544Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 514Carcinoma, Renal Cell 504Hematologic Neoplasms 464Endometrial Neoplasms 463Urinary Bladder Neoplasms 462Colonic Neoplasms 446Lymphoma, Non-Hodgkin 437Sarcoma 435

Interventions

AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Prostate Cancer × 1 year × Clear all
NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

NCT07024277 2025-06-17

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Not yet recruiting
60 enrolled
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡